Abstract
Naturally occurring phenethyl isothiocyanate (PEITC) was previously shown to sensitize human non-small cell lung cancer (NSCLC) cells to the platinum anticancer drug cisplatin (CDDP). Here, CDDP and PEITC were encapsulated in approximately 130 nm liposomes composed of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and L-α-phosphatidylglycerol (EPG). The liposomal formulation enhanced the toxicity of this doublet (1:2 molar ratio of CDDP/PEITC) toward NCI-H596 NSCLC cells; the percent survival of cells was 30.2±6.2% after treatment with the nanoparticle formulation, compared to 50.9±3.5% when administered together free. Thus, such a treatment modality could prove useful in the clinic for the treatment of NSCLC.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / pharmacology*
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Cell Proliferation / drug effects
-
Cell Survival / drug effects
-
Cisplatin / administration & dosage
-
Cisplatin / pharmacology*
-
Dose-Response Relationship, Drug
-
Drug Delivery Systems*
-
Drug Screening Assays, Antitumor
-
Humans
-
Isothiocyanates / administration & dosage
-
Isothiocyanates / pharmacology*
-
Liposomes / administration & dosage
-
Liposomes / chemistry
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / pathology
-
Molecular Structure
-
Nanoparticles / administration & dosage*
-
Nanoparticles / chemistry
-
Particle Size
-
Structure-Activity Relationship
-
Surface Properties
Substances
-
Antineoplastic Agents
-
Isothiocyanates
-
Liposomes
-
phenethyl isothiocyanate
-
Cisplatin